Adial Pharmaceuticals Inc. (NASDAQ:ADIL) on Tuesday commended members of the U.S. Congress for introducing H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act.
The bipartisan legislation aims at expanding research and development of emerging therapies for conditions affecting U.S. veterans, specifically including Alcohol Use Disorder (AUD).
Adial Pharmaceuticals Positioned As Targeted Therapy For Alcohol Use Disorder
Adial’s lead investigational product candidate, AD04, is being developed as a genetically targeted therapy for Alcohol Use Disorder.
AD04 follows a non-abstinence-based treatment approach and aligns with FDA-supported endpoints focused on harm reduction and reduction in heavy drinking days, consistent with direction provided by Congress in the federal Appropriations package.
The company said that …Full story available on Benzinga.com
Arm Is Now Making Its Own Chips
...
Read moreDetails
